Clinical trials: Systemic Lupus
Systemic Lupus Erythematosus
Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study
A Phase 2, Open-Label Extension study to evaluate the long-term safety and tolerability of daxdilimab in participants with Systemic Lupus Erythematosus completing the treatment period of the RECAST SLE clinical study.
- Trial name
- RECAST SLE OLE (NCT05430854)
- Testing
- Daxdilimab
- Where
- 52 sites in United States, Argentina and 7 more
- Volunteers
- 155 people
- Sponsor
- Amgen
Lupus Nephritis (LN)
C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease
This multi-center, open-label, Phase 1/2 study aims to evaluate the safety, tolerability, and preliminary efficacy of C-CAR168, an autologous anti-CD20/BCMA CAR-T therapy, in patients with autoimmune diseases refractory to…
- Trial name
- NCT06935474
- Testing
- C-CAR168
- Where
- United States
- Sponsor
- AbelZeta Inc.
Systemic Lupus Erythematosus
Study of Epratuzumab in Systemic Lupus Erythematosus
Epratuzumab is an investigational antibody designed to help treat Systemic Lupus Erythematosus (SLE). The purpose of the study is to obtain additional long-term information regarding the safety and efficacy of continued…
- Trial name
- NCT00383513
- Testing
- Epratuzumab
- Where
- 10 sites in United States
- Volunteers
- 29 people
- Sponsor
- UCB Pharma
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
This study will have two Phases: Phase 1a and Phase 1b. The goal of this clinical study is to learn more about the study drug KITE-363, to establish dosing, tolerability, safety, and preliminary efficacy of KITE-363 in…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy
- Trial name
- NCT07038447
- Testing
- KITE-363, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 52 people
- Sponsor
- Kite, A Gilead Company
Systemic Lupus Erythematosus
A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184
This study is a Phase I, two-part, open-label study designed to evaluate the effect of repeated doses of GSK2586184 on the pharmacokinetics (PK) of Simvastatin and Rosuvastatin in healthy volunteers (Cohort A), and to evaluate…
- Trial name
- NCT01953835
- Testing
- GSK2586184 standard formulation, Simvastatin, Rosuvastatin
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KP104 in participants with systemic lupus erythematosus (SLE)-Thrombotic microangiopathy (TMA).
- Trial name
- NCT05504187
- Testing
- KP104
- Volunteers
- 24 people
- Sponsor
- Kira Pharmacenticals (US), LLC.
Sjögrens Disease, Systemic Lupus Erythematosus
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL…
- Conditions
- Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Trial name
- NCT06293365
- Testing
- VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
- Where
- 37 sites in United States, Argentina and 6 more
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT03920267
- Testing
- BMS-986165
- Where
- 98 sites in United States, Argentina and 12 more
- Volunteers
- 261 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus
The purpose of this study is to evaluate the safety and tolerability of brentuximab vedotin in adults with active systemic lupus erythematosus (SLE).
- Trial name
- NCT02533570
- Testing
- Brentuximab vedotin
- Where
- 17 sites in United States
- Volunteers
- 20 people
- Sponsor
- Seagen Inc.
Systemic Lupus Erythematosus
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
The purpose of this clinical research study is to learn if addition of abatacept is safe and improves the effectiveness of treatment of patients with active lupus nephritis who are also taking mycophenolate mofetil (MMF) and…
- Trial name
- NCT00430677
- Testing
- Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF)
- Where
- 84 sites in United States, Argentina and 16 more
- Volunteers
- 423 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
A Study of AMG 557 in Adults With Systemic Lupus Erythematosus
This is a Phase 1, randomized, placebo-controlled, double-blind, dose-escalation study of repeat SC doses of AMG 557 in adults with Systemic Lupus Erythematosus.
- Trial name
- NCT00774943
- Testing
- AMG 557
- Where
- 12 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Amgen
SLE
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
- Trial name
- NCT06182969
- Testing
- APG-2575
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ascentage Pharma Group Inc.
Lupus Nephritis
Universal CAR-T Cell Therapy for Refractory Lupus Nephritis
This investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal CAR-T cells targeting BCMA and CD19 in refractory lupus nephritis.
- Trial name
- NCT06681337
- Testing
- BCMA CART + CD19 CART
- Volunteers
- 10 people
- Sponsor
- Bioray Laboratories
Systemic Lupus Erythematosus
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
This is a 2-part study of GSK5926371 in participants with autoimmune rheumatic diseases (ARD). In part 1, participants will receive different doses of GSK5926371 to find a suitable priming dose.
- Trial name
- ELEVATE-1 (NCT07371468)
- Testing
- GSK5926371
- Where
- 19 sites in Argentina, Brazil and 7 more
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
The purpose of this study is to evaluate the safety and efficacy of repeated intravenous infusions of the study drug BT063 in patients with Systemic Lupus Erythematosus (SLE) compared with people who receive a placebo.
- Trial name
- BT063 in SLE (NCT02554019)
- Testing
- BT063
- Where
- 14 sites in Belarus, Georgia and 2 more
- Volunteers
- 36 people
- Sponsor
- Biotest
Systemic Lupus Eythematosus (SLE)
Leflunomide in Systemic Lupus Erythematosus
A pilot study to evaluate the efficacy and safety of leflunomide in SLE patients with active disease who are refractory to cyclophosphamide
- Trial name
- NCT00637819
- Testing
- Leflunomide
- Where
- Hong Kong
- Volunteers
- 27 people
- Sponsor
- Sanofi
Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN)
A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
This Phase 1, open label, dose escalation study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of HB2198, a tetravalent bispecific anti CD19/CD20 antibody, in adults with…
- Conditions
- Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Extra-renal Lupus (ERL)
- Trial name
- NCT07491900
- Testing
- HB2198
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Hinge Bio
Difficult to Treat Systemic Lupus Erythematosus
Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
This study is an open label, single arm exploratory clinical trial of IC19 CAR-T cell therapy for refractory systemic lupus erythematosus.
- Trial name
- IC19 CAR-T (NCT06886919)
- Testing
- Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells
- Volunteers
- 6 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Lupus Nephritis
Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study
This study consists of a 28-week placebo-controlled double-blind inter-group efficacy study in steroid refractory Lupus Nephritis patients.
- Trial name
- NCT00429377
- Testing
- tacrolimus
- Where
- 7 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Astellas Pharma Inc